Patients with metastatic prostate cancer are known to harbor pathogenic variants in a cancer predisposition genes, including BRCA1 and BRCA2, far more frequently than patients with localized prostate cancer [34], therefore genetic testing of all patients with metastatic prostate cancer may be beneficial, especially since screening and treatment options are available [29]. Here, BRCA1 is linked to metastatic prostate carcinoma.